Peptide Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Branded, Generic, Innovative and Other Types), Route of Administration, Manufacturer Type, Molecule Type, Technology, Application, End User and By Geography

Peptide Therapeutics Market Forecasts to 2030 - Global Analysis By Type (Branded, Generic, Innovative and Other Types), Route of Administration, Manufacturer Type, Molecule Type, Technology, Application, End User and By Geography


According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $49.15 billion in 2024 and is expected to reach $76.41 billion by 2030 growing at a CAGR of 7.63% during the forecast period. Peptide therapeutics are a new and exciting class of pharmaceuticals that target and modify particular physiological pathways by using peptides, which are short chains of amino acids. With their exceptional selectivity and capacity to engage with a wide variety of biological targets, such as hormones, enzymes, and receptors, these treatments are particularly useful. Comparing new treatments to older small-molecule medications, this precision allows for the development of therapies with fewer side effects. Moreover, utilizing innovative methods to treat ailments like diabetes, cancer, and bacterial infections, peptide therapeutics are used in oncology, endocrinology, and infectious diseases, among other medical specialties.

According to the American Diabetes Association, peptide therapeutics represent a significant advancement in the treatment of diabetes, offering improved glucose control and reduced side effects compared to conventional therapies.

Market Dynamics:

Driver:

Growing rate of chronic illnesses

The increasing prevalence of chronic illnesses worldwide, including diabetes, cancer, heart disease, and neurological disorders, is driving up demand for more sophisticated treatment alternatives. Peptide therapeutics presents a promising substitute for conventional therapies because of their capacity to precisely target diseased cells and pathways. GLP-1 receptor agonists, for example, are peptide medications that have demonstrated superior efficacy in glycemic control in diabetes. Furthermore, the market for peptide therapeutics is being driven by the increasing number of patients with chronic conditions, which is driving the demand for safer and more effective treatments.

Restraint:

Elevated production expenses

Peptide therapeutics is made using costly and intricate synthesis techniques like recombinant DNA technology and solid-phase peptide synthesis (SPPS). To guarantee the desired product's purity and effectiveness, these procedures call for expensive machinery, high-purity reagents, and stringent quality control procedures. Additionally, it can be unaffordable to scale up production from a laboratory to a commercial scale. Because of their high production costs, these products end up being more expensive, which can restrict their affordability and accessibility, particularly in developing nations where healthcare budgets are tight.

Opportunity:

Growth in emerging markets

Peptide therapeutics has a lot of room to grow in emerging markets, especially in Asia-Pacific, Latin America, and Africa. These areas are seeing increases in the cost of healthcare, a rise in the incidence of chronic illnesses, and advancements in the infrastructure of healthcare. Improving access to cutting-edge medical treatments is the main priority for these regions' governments and healthcare institutions. Companies can access a sizable and expanding patient population by judiciously entering these markets. Furthermore, smoother entry and expansion into new markets can be facilitated by working with regional healthcare providers and adjusting to local regulatory requirements.

Threat:

Fierce rivalry between biologics and small molecules

Market competitors for peptide therapeutics include well-known small-molecule medications and biologics. Because of their longer shelf life, oral bioavailability, and lower production costs, small-molecule drugs are typically preferred. Biologics are widely used in the treatment of a wide range of chronic and complex diseases because they have high specificity and efficacy, such as gene therapies and monoclonal antibodies. Moreover, peptide therapies have a difficult time taking off due to the established market positions of these alternatives; in order to successfully compete, they must significantly differ from the competition in terms of efficacy, safety, or convenience.

Covid-19 Impact:

The peptide therapeutics market was affected by the COVID-19 pandemic in a variety of ways, which both hampered and accelerated the industry's growth. Research and production capacities were momentarily hampered by supply chain disruptions and the reallocation of healthcare funds to pandemic management. But the pressing need for efficient medications and vaccines brought peptide-based therapies' potential to light, resulting in more funding and quicker regulatory approvals for related goods. Additionally, the pandemic also brought attention to the significance of creative drug delivery methods and robust supply chains, which sparked developments and adjustments that might eventually help the market.

The Innovative segment is expected to be the largest during the forecast period

The market for peptide therapeutics is dominated by the innovative segment. This dominance is fueled by the ongoing research and development of innovative peptide medications, which provide focused therapies for a variety of illnesses, such as diabetes, cardiovascular disease, and cancer. Novel peptides are generally engineered to possess heightened selectivity, effectiveness, and safety characteristics, filling gaps in the medical field and providing better therapeutic alternatives than established therapies. Furthermore, growth in this market has been driven by significant R&D expenditures as well as regulatory support for innovative treatments.

The Oral segment is expected to have the highest CAGR during the forecast period

In the peptide therapeutics market, the oral segment is anticipated to grow at the highest CAGR. Peptide medications have historically had difficulty being administered orally because of their low bioavailability and vulnerability to enzymatic breakdown in the gastrointestinal system. But new developments in drug delivery technologies are changing this, like the creation of oral formulations that prevent peptides from degrading and improve their absorption. Moreover, enteric coatings, enzyme inhibitors, and nanoparticle carriers are some of the innovations that are making oral peptide therapeutics more appealing and feasible.

Region with largest share:

The market for peptide therapeutics is dominated by North America. Numerous factors, such as a strong research and development base, a high incidence of chronic illnesses, and advantageous regulatory frameworks, are responsible for this dominance. Contributing to the region's leading position are important pharmaceutical and biotechnology companies, as well as a strong emphasis on innovation and technological advancements. Additionally, growing patient and healthcare professional awareness of the advantages of peptide therapeutics, along with rising investments in personalized therapies and precision medicine, are driving market growth in North America.

Region with highest CAGR:

The peptide therapeutics market is expected to grow at the highest CAGR in the Asia-Pacific area. The biopharmaceutical industry is growing, chronic disease prevalence is rising, healthcare costs are rising, and R&D spending is rising, among other factors driving this growth. China, India, Japan, and South Korea are becoming major players in the global pharmaceutical industry, focusing on the development of novel treatments such as peptide drugs. Furthermore, the Asia-Pacific region offers substantial prospects for market expansion due to favourable government initiatives, improving healthcare infrastructure, and a sizable patient population.

Key players in the market

Some of the key players in Peptide Therapeutics market include Eli Lilly & Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bausch Health Companies Inc, Ever Neuro Pharma GmbH, AbbVie, Inc., Ironwood Pharmaceuticals Inc., Sanofi SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd. And Teva Pharmaceutical Industries Ltd.

Key Developments:

In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies.

In January 2024, Roche and MOMA Therapeutics have signed a strategic partnership and licencing agreement for discovering drug targets for cancer. Under the alliance, Roche will obtain access to MOMA’s KnowledgeBase platform to identify and prosecute new drug targets that are involved in the growth and survival of cancer cells.

In October 2023, French biotech company Mablink has entered an agreement to be acquired by Eli Lilly. The deal is subject to approval from the French Ministry of the Economy. Lilly plans to utilise Mablink’s PSARLink technology, which disguises cancer-killing molecules, allowing them to be delivered precisely to cancer cells while sparing healthy cells. The technology will broaden the use of antibody-drug conjugates (ADCs).

Types Covered:
• Branded
• Generic
• Innovative
• Other Types

Route of Administrations Covered:
• Parenteral
• Oral
• Mucosal
• Injection
• Nasal
• Other Routes of Administrations

Manufacturer Types Covered:
• In-house
• CMO
• Other Manufacturer Types

Molecule Types Covered:
• Vasopressin
• Somatostatin
• Natriuretic
• Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
• Insulins
• Immunopeptide
• Glucagon and Analogs
• Calcitonin
• Other Molecule Types

Technologies Covered:
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology
• Other Technologies

Applications Covered:
• Metabolic Disorders
• Cancer
• Cardiovascular Disorders
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Infectious Diseases
• Respiratory Disorders
• Pain Management
• Rental Disorders
• Dermatology
• Other Applications

End Users Covered:
• Pharmaceutical and Biotechnology Industries
• Hospitals
• Contract Research Organization
• Academic and Research Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements











According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $49.15 billion in 2024 and is expected to reach $76.41 billion by 2030 growing at a CAGR of 7.63% during the forecast period. Peptide therapeutics are a new and exciting class of pharmaceuticals that target and modify particular physiological pathways by using peptides, which are short chains of amino acids. With their exceptional selectivity and capacity to engage with a wide variety of biological targets, such as hormones, enzymes, and receptors, these treatments are particularly useful. Comparing new treatments to older small-molecule medications, this precision allows for the development of therapies with fewer side effects. Moreover, utilizing innovative methods to treat ailments like diabetes, cancer, and bacterial infections, peptide therapeutics are used in oncology, endocrinology, and infectious diseases, among other medical specialties.

According to the American Diabetes Association, peptide therapeutics represent a significant advancement in the treatment of diabetes, offering improved glucose control and reduced side effects compared to conventional therapies.

Market Dynamics:

Driver:

Growing rate of chronic illnesses

The increasing prevalence of chronic illnesses worldwide, including diabetes, cancer, heart disease, and neurological disorders, is driving up demand for more sophisticated treatment alternatives. Peptide therapeutics presents a promising substitute for conventional therapies because of their capacity to precisely target diseased cells and pathways. GLP-1 receptor agonists, for example, are peptide medications that have demonstrated superior efficacy in glycemic control in diabetes. Furthermore, the market for peptide therapeutics is being driven by the increasing number of patients with chronic conditions, which is driving the demand for safer and more effective treatments.

Restraint:

Elevated production expenses

Peptide therapeutics is made using costly and intricate synthesis techniques like recombinant DNA technology and solid-phase peptide synthesis (SPPS). To guarantee the desired product's purity and effectiveness, these procedures call for expensive machinery, high-purity reagents, and stringent quality control procedures. Additionally, it can be unaffordable to scale up production from a laboratory to a commercial scale. Because of their high production costs, these products end up being more expensive, which can restrict their affordability and accessibility, particularly in developing nations where healthcare budgets are tight.

Opportunity:

Growth in emerging markets

Peptide therapeutics has a lot of room to grow in emerging markets, especially in Asia-Pacific, Latin America, and Africa. These areas are seeing increases in the cost of healthcare, a rise in the incidence of chronic illnesses, and advancements in the infrastructure of healthcare. Improving access to cutting-edge medical treatments is the main priority for these regions' governments and healthcare institutions. Companies can access a sizable and expanding patient population by judiciously entering these markets. Furthermore, smoother entry and expansion into new markets can be facilitated by working with regional healthcare providers and adjusting to local regulatory requirements.

Threat:

Fierce rivalry between biologics and small molecules

Market competitors for peptide therapeutics include well-known small-molecule medications and biologics. Because of their longer shelf life, oral bioavailability, and lower production costs, small-molecule drugs are typically preferred. Biologics are widely used in the treatment of a wide range of chronic and complex diseases because they have high specificity and efficacy, such as gene therapies and monoclonal antibodies. Moreover, peptide therapies have a difficult time taking off due to the established market positions of these alternatives; in order to successfully compete, they must significantly differ from the competition in terms of efficacy, safety, or convenience.

Covid-19 Impact:

The peptide therapeutics market was affected by the COVID-19 pandemic in a variety of ways, which both hampered and accelerated the industry's growth. Research and production capacities were momentarily hampered by supply chain disruptions and the reallocation of healthcare funds to pandemic management. But the pressing need for efficient medications and vaccines brought peptide-based therapies' potential to light, resulting in more funding and quicker regulatory approvals for related goods. Additionally, the pandemic also brought attention to the significance of creative drug delivery methods and robust supply chains, which sparked developments and adjustments that might eventually help the market.

The Innovative segment is expected to be the largest during the forecast period

The market for peptide therapeutics is dominated by the innovative segment. This dominance is fueled by the ongoing research and development of innovative peptide medications, which provide focused therapies for a variety of illnesses, such as diabetes, cardiovascular disease, and cancer. Novel peptides are generally engineered to possess heightened selectivity, effectiveness, and safety characteristics, filling gaps in the medical field and providing better therapeutic alternatives than established therapies. Furthermore, growth in this market has been driven by significant R&D expenditures as well as regulatory support for innovative treatments.

The Oral segment is expected to have the highest CAGR during the forecast period

In the peptide therapeutics market, the oral segment is anticipated to grow at the highest CAGR. Peptide medications have historically had difficulty being administered orally because of their low bioavailability and vulnerability to enzymatic breakdown in the gastrointestinal system. But new developments in drug delivery technologies are changing this, like the creation of oral formulations that prevent peptides from degrading and improve their absorption. Moreover, enteric coatings, enzyme inhibitors, and nanoparticle carriers are some of the innovations that are making oral peptide therapeutics more appealing and feasible.

Region with largest share:

The market for peptide therapeutics is dominated by North America. Numerous factors, such as a strong research and development base, a high incidence of chronic illnesses, and advantageous regulatory frameworks, are responsible for this dominance. Contributing to the region's leading position are important pharmaceutical and biotechnology companies, as well as a strong emphasis on innovation and technological advancements. Additionally, growing patient and healthcare professional awareness of the advantages of peptide therapeutics, along with rising investments in personalized therapies and precision medicine, are driving market growth in North America.

Region with highest CAGR:

The peptide therapeutics market is expected to grow at the highest CAGR in the Asia-Pacific area. The biopharmaceutical industry is growing, chronic disease prevalence is rising, healthcare costs are rising, and R&D spending is rising, among other factors driving this growth. China, India, Japan, and South Korea are becoming major players in the global pharmaceutical industry, focusing on the development of novel treatments such as peptide drugs. Furthermore, the Asia-Pacific region offers substantial prospects for market expansion due to favourable government initiatives, improving healthcare infrastructure, and a sizable patient population.

Key players in the market

Some of the key players in Peptide Therapeutics market include Eli Lilly & Company, AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., Bausch Health Companies Inc, Ever Neuro Pharma GmbH, AbbVie, Inc., Ironwood Pharmaceuticals Inc., Sanofi SA, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Amgen Inc., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd. And Teva Pharmaceutical Industries Ltd.

Key Developments:

In May 2024, AstraZeneca has entered a worldwide licence and option agreement with Nona Biosciences for a preclinical monoclonal antibody. The deal focuses on the development of the antibody to develop targeted tumour therapies.

In January 2024, Roche and MOMA Therapeutics have signed a strategic partnership and licencing agreement for discovering drug targets for cancer. Under the alliance, Roche will obtain access to MOMA’s KnowledgeBase platform to identify and prosecute new drug targets that are involved in the growth and survival of cancer cells.

In October 2023, French biotech company Mablink has entered an agreement to be acquired by Eli Lilly. The deal is subject to approval from the French Ministry of the Economy. Lilly plans to utilise Mablink’s PSARLink technology, which disguises cancer-killing molecules, allowing them to be delivered precisely to cancer cells while sparing healthy cells. The technology will broaden the use of antibody-drug conjugates (ADCs).

Types Covered:
• Branded
• Generic
• Innovative
• Other Types

Route of Administrations Covered:
• Parenteral
• Oral
• Mucosal
• Injection
• Nasal
• Other Routes of Administrations

Manufacturer Types Covered:
• In-house
• CMO
• Other Manufacturer Types

Molecule Types Covered:
• Vasopressin
• Somatostatin
• Natriuretic
• Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
• Insulins
• Immunopeptide
• Glucagon and Analogs
• Calcitonin
• Other Molecule Types

Technologies Covered:
• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology
• Other Technologies

Applications Covered:
• Metabolic Disorders
• Cancer
• Cardiovascular Disorders
• Gastrointestinal Disorders
• Central Nervous System Disorders
• Infectious Diseases
• Respiratory Disorders
• Pain Management
• Rental Disorders
• Dermatology
• Other Applications

End Users Covered:
• Pharmaceutical and Biotechnology Industries
• Hospitals
• Contract Research Organization
• Academic and Research Institutes
• Other End Users

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements


1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Peptide Therapeutics Market, By Type
5.1 Introduction
5.2 Branded
5.3 Generic
5.4 Innovative
5.5 Other Types
6 Global Peptide Therapeutics Market, By Route of Administration
6.1 Introduction
6.2 Parenteral
6.3 Oral
6.4 Mucosal
6.5 Injection
6.6 Nasal
6.7 Other Routes of Administrations
7 Global Peptide Therapeutics Market, By Manufacturer Type
7.1 Introduction
7.2 In-house
7.3 CMO
7.4 Other Manufacturer Types
8 Global Peptide Therapeutics Market, By Molecule Type
8.1 Introduction
8.2 Vasopressin
8.3 Somatostatin
8.4 Natriuretic
8.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
8.6 Insulins
8.7 Immunopeptide
8.8 Glucagon and Analogs
8.9 Calcitonin
8.10 Other Molecule Types
9 Global Peptide Therapeutics Market, By Technology
9.1 Introduction
9.2 Solid Phase Peptide Synthesis (SPPS)
9.3 Liquid Phase Peptide Synthesis (LPPS)
9.4 Hybrid Technology
9.5 Other Technologies
10 Global Peptide Therapeutics Market, By Application
10.1 Introduction
10.2 Metabolic Disorders
10.3 Cancer
10.4 Cardiovascular Disorders
10.5 Gastrointestinal Disorders
10.6 Central Nervous System Disorders
10.7 Infectious Diseases
10.8 Respiratory Disorders
10.9 Pain Management
10.10 Rental Disorders
10.11 Dermatology
10.12 Other Applications
11 Global Peptide Therapeutics Market, By End User
11.1 Introduction
11.2 Pharmaceutical and Biotechnology Industries
11.3 Hospitals
11.4 Contract Research Organization
11.5 Academic and Research Institutes
11.6 Other End Users
12 Global Peptide Therapeutics Market, By Geography
12.1 Introduction
12.2 North America
12.2.1 US
12.2.2 Canada
12.2.3 Mexico
12.3 Europe
12.3.1 Germany
12.3.2 UK
12.3.3 Italy
12.3.4 France
12.3.5 Spain
12.3.6 Rest of Europe
12.4 Asia Pacific
12.4.1 Japan
12.4.2 China
12.4.3 India
12.4.4 Australia
12.4.5 New Zealand
12.4.6 South Korea
12.4.7 Rest of Asia Pacific
12.5 South America
12.5.1 Argentina
12.5.2 Brazil
12.5.3 Chile
12.5.4 Rest of South America
12.6 Middle East & Africa
12.6.1 Saudi Arabia
12.6.2 UAE
12.6.3 Qatar
12.6.4 South Africa
12.6.5 Rest of Middle East & Africa
13 Key Developments
13.1 Agreements, Partnerships, Collaborations and Joint Ventures
13.2 Acquisitions & Mergers
13.3 New Product Launch
13.4 Expansions
13.5 Other Key Strategies
14 Company Profiling
14.1 Eli Lilly & Company
14.2 AstraZeneca PLC
14.3 F. Hoffmann-La Roche Ltd.
14.4 Novartis AG
14.5 Pfizer Inc.
14.6 Bausch Health Companies Inc
14.7 Ever Neuro Pharma GmbH
14.8 AbbVie, Inc.
14.9 Ironwood Pharmaceuticals Inc.
14.10 Sanofi SA
14.11 Novo Nordisk A/S
14.12 Takeda Pharmaceutical Company Limited
14.13 Amgen Inc.
14.14 GlaxoSmithKline plc
14.15 Sun Pharmaceutical Industries Ltd.
14.16 Teva Pharmaceutical Industries Ltd.
List of Tables
Table 1 Global Peptide Therapeutics Market Outlook, By Region (2022-2030) ($MN)
Table 2 Global Peptide Therapeutics Market Outlook, By Type (2022-2030) ($MN)
Table 3 Global Peptide Therapeutics Market Outlook, By Branded (2022-2030) ($MN)
Table 4 Global Peptide Therapeutics Market Outlook, By Generic (2022-2030) ($MN)
Table 5 Global Peptide Therapeutics Market Outlook, By Innovative (2022-2030) ($MN)
Table 6 Global Peptide Therapeutics Market Outlook, By Other Types (2022-2030) ($MN)
Table 7 Global Peptide Therapeutics Market Outlook, By Route of Administration (2022-2030) ($MN)
Table 8 Global Peptide Therapeutics Market Outlook, By Parenteral (2022-2030) ($MN)
Table 9 Global Peptide Therapeutics Market Outlook, By Oral (2022-2030) ($MN)
Table 10 Global Peptide Therapeutics Market Outlook, By Mucosal (2022-2030) ($MN)
Table 11 Global Peptide Therapeutics Market Outlook, By Injection (2022-2030) ($MN)
Table 12 Global Peptide Therapeutics Market Outlook, By Nasal (2022-2030) ($MN)
Table 13 Global Peptide Therapeutics Market Outlook, By Other Routes of Administrations (2022-2030) ($MN)
Table 14 Global Peptide Therapeutics Market Outlook, By Manufacturer Type (2022-2030) ($MN)
Table 15 Global Peptide Therapeutics Market Outlook, By In-house (2022-2030) ($MN)
Table 16 Global Peptide Therapeutics Market Outlook, By CMO (2022-2030) ($MN)
Table 17 Global Peptide Therapeutics Market Outlook, By Other Manufacturer Types (2022-2030) ($MN)
Table 18 Global Peptide Therapeutics Market Outlook, By Molecule Type (2022-2030) ($MN)
Table 19 Global Peptide Therapeutics Market Outlook, By Vasopressin (2022-2030) ($MN)
Table 20 Global Peptide Therapeutics Market Outlook, By Somatostatin (2022-2030) ($MN)
Table 21 Global Peptide Therapeutics Market Outlook, By Natriuretic (2022-2030) ($MN)
Table 22 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2022-2030) ($MN)
Table 23 Global Peptide Therapeutics Market Outlook, By Insulins (2022-2030) ($MN)
Table 24 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2022-2030) ($MN)
Table 25 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2022-2030) ($MN)
Table 26 Global Peptide Therapeutics Market Outlook, By Calcitonin (2022-2030) ($MN)
Table 27 Global Peptide Therapeutics Market Outlook, By Other Molecule Types (2022-2030) ($MN)
Table 28 Global Peptide Therapeutics Market Outlook, By Technology (2022-2030) ($MN)
Table 29 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2022-2030) ($MN)
Table 30 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2022-2030) ($MN)
Table 31 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2022-2030) ($MN)
Table 32 Global Peptide Therapeutics Market Outlook, By Other Technologies (2022-2030) ($MN)
Table 33 Global Peptide Therapeutics Market Outlook, By Application (2022-2030) ($MN)
Table 34 Global Peptide Therapeutics Market Outlook, By Metabolic Disorders (2022-2030) ($MN)
Table 35 Global Peptide Therapeutics Market Outlook, By Cancer (2022-2030) ($MN)
Table 36 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorders (2022-2030) ($MN)
Table 37 Global Peptide Therapeutics Market Outlook, By Gastrointestinal Disorders (2022-2030) ($MN)
Table 38 Global Peptide Therapeutics Market Outlook, By Central Nervous System Disorders (2022-2030) ($MN)
Table 39 Global Peptide Therapeutics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
Table 40 Global Peptide Therapeutics Market Outlook, By Respiratory Disorders (2022-2030) ($MN)
Table 41 Global Peptide Therapeutics Market Outlook, By Pain Management (2022-2030) ($MN)
Table 42 Global Peptide Therapeutics Market Outlook, By Rental Disorders (2022-2030) ($MN)
Table 43 Global Peptide Therapeutics Market Outlook, By Dermatology (2022-2030) ($MN)
Table 44 Global Peptide Therapeutics Market Outlook, By Other Applications (2022-2030) ($MN)
Table 45 Global Peptide Therapeutics Market Outlook, By End User (2022-2030) ($MN)
Table 46 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2022-2030) ($MN)
Table 47 Global Peptide Therapeutics Market Outlook, By Hospitals (2022-2030) ($MN)
Table 48 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2022-2030) ($MN)
Table 49 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2022-2030) ($MN)
Table 50 Global Peptide Therapeutics Market Outlook, By Other End Users (2022-2030) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings